The world's first pill to treat multiple sclerosis has today been given the green light by NICE. Current treatments are injections and hospital infusions.
NICE, (National Institute for Health and Clinical Excellence) has recommended fingolimod for the treatment of highly active relapsing remitting multiple sclerosis, confirming it as a valuable, innovative and cost-effective therapy.
There are 4,000 people living with MS in Wales and three new people diagnosed every week. The cost of MS in Wales is £67 million a year, approximately £17,000 per person with the condition.